Paragangliomas Completed Phase 1 Trials for Cixutumumab (DB12250)

Back to Paragangliomas

Also known as: Paraganglioma / Paraganglion neoplasm / Paraganglion neoplasm NOS / Neoplasm of paraganglion (disorder) / [M]Paraganglioma NOS (morphologic abnormality) / Gangliocytic paraganglioma (disorder) / Gangliocytic paraganglioma (morphologic abnormality) / Paraganglioma (morphologic abnormality) / Paraganglioma (disorder)

IndicationStatusPhase
DBCOND0051744 (Paragangliomas)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01204476Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaTreatment